Lipocalin-2 Expression and Function in Pancreatic Diseases

Overview

Journal Pancreatology

Specialties Endocrinology
Gastroenterology

Date 2020 Jan 15

PMID 31932215

Citations 14

Authors

Kristyn Gumpper

Andrew William Dangel

Valentina Pita-Grisanti

Somashekar G Krishna

Luis F Lara

Thomas Mace

Georgios I Papachristou

Darwin L Conwell

Phil A Hart

Zobeida Cruz-Monserrate

Affiliations

Soon will be listed here.

Abstract

Lipocalin-2 (LCN2) is a secreted molecule, expressed in various cell types, that is involved in the progression of numerous diseases and disorders. The biological functions and expression levels of LCN2 in diseases including pancreatic cancer, pancreatitis (acute and chronic), and diabetes mellitus, suggest the potential role of LCN2 as a biomarker and/or therapeutic target. However, findings on the role of LCN2 in pancreatic diseases have been contradictory. In pancreatic cancer and pancreatitis, LCN2 has been identified as a potential biomarker; increased expression levels in various biological specimens correlate with the presence of the disease and may be able to differentiate cancer and chronic pancreatitis from healthy subjects. LCN2 is also known to be an adipokine; it is upregulated in obesity and is a common co-factor in the development of pancreatic diseases. Emerging research suggests LCN2 is elevated in type 2 diabetes mellitus, but the exact role of LCN2 in this disease is not clear. In this review, we summarize research on LCN2 as it relates to pancreatic diseases, highlighting the discrepancies in the literature. By explaining and clarifying the role of LCN2 in these disorders, we aim to promote research in developing novel diagnostic and treatment strategies to reduce the burden of pancreatic diseases.

Citing Articles

Upregulated Matrisomal Proteins and Extracellular Matrix Mechanosignaling Underlie Obesity-Associated Promotion of Pancreatic Ductal Adenocarcinoma.

Waldron R, Lugea A, Chang H, Su H, Quiros C, Lewis M Cancers (Basel). 2024; 16(8).

PMID: 38672675 PMC: 11048773. DOI: 10.3390/cancers16081593.

Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2.

Lee E, Lee J, Kim D, Lee Y, Jo Y, Dao T Exp Mol Med. 2024; 56(4):1001-1012.

PMID: 38622198 PMC: 11058876. DOI: 10.1038/s12276-024-01213-2.

Diagnostic and Prognostic Biomarkers of Chronic Pancreatitis: A Conceptual Framework Based on the PRoBE Design.

Yadav D, Conwell D, Pandol S, Steen H, Feng Z, Li L Gastroenterology. 2024; 166(6):957-962.e3.

PMID: 38423226 PMC: 11102843. DOI: 10.1053/j.gastro.2024.02.030.

Systemic Neutrophil Gelatinase-Associated Lipocalin Alterations in Chronic Pancreatitis: A Multicenter, Cross-Sectional Study.

Gumpper-Fedus K, Chasser K, Pita-Grisanti V, Torok M, Pfau T, Mace T Clin Transl Gastroenterol. 2024; 15(4):e00686.

PMID: 38284831 PMC: 11042777. DOI: 10.14309/ctg.0000000000000686.

Decoding the obesity-cancer connection: lessons from preclinical models of pancreatic adenocarcinoma.

Ruiz C, Garcia C, Jacox J, Lawres L, Muzumdar M Life Sci Alliance. 2023; 6(11).

PMID: 37648285 PMC: 10474221. DOI: 10.26508/lsa.202302228.

References

El-Hadidi H, Samir N, Shaker O, Otb S . Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to metabolic syndrome. Arch Dermatol Res. 2013; 306(3):239-45. DOI: 10.1007/s00403-013-1414-x. View

Tso A, Xu A, Chow W, Lam K . Adipose tissue and the metabolic syndrome: focusing on adiponectin and several novel adipokines. Biomark Med. 2010; 2(3):239-52. DOI: 10.2217/17520363.2.3.239. View

Argani P, Rosty C, Reiter R, Wilentz R, Murugesan S, Leach S . Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001; 61(11):4320-4. View

Malli A, Li F, Conwell D, Cruz-Monserrate Z, Hussan H, Krishna S . The Burden of Systemic Adiposity on Pancreatic Disease: Acute Pancreatitis, Non-Alcoholic Fatty Pancreas Disease, and Pancreatic Cancer. JOP. 2018; 18(5):365-368. PMC: 5826578. View

Kjeldsen L, Johnsen A, Sengelov H, Borregaard N . Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993; 268(14):10425-32. View

Komar H, Hart P, Cruz-Monserrate Z, Conwell D, Lesinski G . Local and Systemic Expression of Immunomodulatory Factors in Chronic Pancreatitis. Pancreas. 2017; 46(8):986-993. PMC: 5774026. DOI: 10.1097/MPA.0000000000000896. View

Zabron A, Horneffer-van der Sluis V, Wadsworth C, Laird F, Gierula M, Thillainayagam A . Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease. Am J Gastroenterol. 2011; 106(9):1711-7. DOI: 10.1038/ajg.2011.187. View

Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C . The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci U S A. 2008; 105(37):14058-63. PMC: 2544578. DOI: 10.1073/pnas.0710846105. View

Leung L, Radulovich N, Zhu C, Organ S, Bandarchi B, Pintilie M . Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One. 2012; 7(10):e46677. PMC: 3464270. DOI: 10.1371/journal.pone.0046677. View

10.

Fischbach M, Lin H, Liu D, Walsh C . How pathogenic bacteria evade mammalian sabotage in the battle for iron. Nat Chem Biol. 2006; 2(3):132-8. DOI: 10.1038/nchembio771. View

11.

Rybak K, Sporek M, Gala-Bladzinska A, Mazur-Laskowska M, Dumnicka P, Walocha J . [Urinalysis in patients at the early stage of acute pancreatitis]. Przegl Lek. 2016; 73(2):88-92. View

12.

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W . Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019; 178(4):795-806.e12. PMC: 7288240. DOI: 10.1016/j.cell.2019.07.008. View

13.

Chakraborty S, Kaur S, Guha S, Batra S . The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012; 1826(1):129-69. PMC: 3362670. DOI: 10.1016/j.bbcan.2012.03.008. View

14.

Kaur S, Baine M, Guha S, Ochi N, Chakraborty S, Mallya K . Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas. Pancreas. 2012; 42(3):494-501. PMC: 3578014. DOI: 10.1097/MPA.0b013e31826a8597. View

15.

Tong Z, Kunnumakkara A, Wang H, Matsuo Y, Diagaradjane P, Harikumar K . Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res. 2008; 68(15):6100-8. PMC: 2714276. DOI: 10.1158/0008-5472.CAN-08-0540. View

16.

Ishii A, Katsuura G, Imamaki H, Kimura H, Mori K, Kuwabara T . Obesity-promoting and anti-thermogenic effects of neutrophil gelatinase-associated lipocalin in mice. Sci Rep. 2017; 7(1):15501. PMC: 5686189. DOI: 10.1038/s41598-017-15825-4. View

17.

Siddappa P, Kochhar R, Sarotra P, Medhi B, Jha V, Gupta V . Neutrophil gelatinase-associated lipocalin: An early biomarker for predicting acute kidney injury and severity in patients with acute pancreatitis. JGH Open. 2019; 3(2):105-110. PMC: 6487831. DOI: 10.1002/jgh3.12112. View

18.

Delanaye P, Rozet E, Krzesinski J, Cavalier E . Urinary NGAL measurement: biological variation and ratio to creatinine. Clin Chim Acta. 2010; 412(3-4):390. DOI: 10.1016/j.cca.2010.10.011. View

19.

Venkatesha S, Hanai J, Seth P, Karumanchi S, Sukhatme V . Lipocalin 2 antagonizes the proangiogenic action of ras in transformed cells. Mol Cancer Res. 2006; 4(11):821-9. DOI: 10.1158/1541-7786.MCR-06-0110. View

20.

Hvidberg V, Jacobsen C, Strong R, Cowland J, Moestrup S, Borregaard N . The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 2005; 579(3):773-7. DOI: 10.1016/j.febslet.2004.12.031. View